Evidence Grade C — Moderate human evidence. 18 published studies, 13 human. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Livagen is a synthetic tetrapeptide from the Khavinson bioregulator programme in Russia, proposed to target liver tissue. No human clinical trials have been conducted and it has no approval from any major regulatory agency. The evidence consists of laboratory cell studies from the originating research group.
Livagen is also known by these brand and alternate names:
18 published studies: 13 human, 5 animal, 3 in-vitro, 0 reviews
Livagen has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of ex vivo lymphocyte studies and the broader Khavinson bioregulation research programme.
As with other Khavinson bioregulator peptides, the proposed mechanisms have not been independently validated through conventional drug development processes. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Livagen may reverse age-related chromatin condensation in liver cells. Studies using lymphocytes from elderly donors reported activation of ribosomal genes and chromatin structural changes. These observations are part of the Khavinson bioregulation theoretical framework.
Research suggests Livagen has somewhat stronger mechanistic evidence than most Khavinson peptides, with studies on chromatin structure changes and enzyme activity published in indexed journals. However, no registered human clinical trials exist, no pharmacokinetic data are available, and there is no independent Western replication. As with all Khavinson bioregulator peptides, the proposed tissue-specific effects have not been validated through conventional drug development processes. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Livagen sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Livagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA). Its molecular weight is 461.5 Da with the molecular formula C18H31N5O9 (CAS 195875-84-4, PubChem CID 87919683). Developed by Vladimir Khavinson as part of the cytomedine program, Livagen targets hepatic tissue. No formal pharmacokinetic data exist. Among the Khavinson bioregulators, Livagen has some of the stronger mechanistic evidence, particularly for chromatin remodeling and enkephalinase inhibition.
Research suggests Livagen's primary mechanism centers on chromatin decondensation, specifically de-heterochromatinization of chromatin that becomes pathologically condensed during aging. Effects include decondensation of pericentromeric structural heterochromatin, activation of ribosomal genes, and release of genes repressed by age-related condensation. Livagen also demonstrates enkephalinase inhibition with IC50 of 20 microM, more potent than puromycin and leupeptin. By comparison, Epitalon's IC50 for the same enzymes is 500 microM (25-fold less potent). Radioreceptor assay confirmed Livagen does NOT directly interact with opioid receptors.
Chromatin activation studies (Khavinson et al. 2002) used lymphocytes from elderly donors (60-80 years) at St. Petersburg and Tbilisi State University (Georgia), showing activation of ribosomal genes and decondensation of pericentromeric heterochromatin. Comparison with Vilon showed Vilon did NOT induce pericentromeric heterochromatin decondensation, indicating Livagen has broader chromatin-remodeling capacity. Enkephalinase inhibition (Kost et al. 2003, Russian Academy of Medical Sciences, Moscow) confirmed IC50 of 20 microM. In liver pathology models, Livagen normalized immune and antioxidant status and restored liver function.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 4 vendor listings
View pricing data across vendors and countries for Livagen
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, approved August 2024). It is the first FDA-approved PTH replacement therapy for hypoparathyroidism, a condition that previously had no approved hormone replacement and was managed only with high doses of calcium supplements and active vitamin D — an approach that does not fully normalise calcium metabolism. In the PaTHway trial, 79% of patients achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to 5% on placebo. This represents a fundamental shift in managing hypoparathyroidism — from supplementation to actual hormone replacement. Patients also showed improvements in kidney function markers and bone metabolism parameters.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
